SCHEDULE: T. Rowe Price Discloses 4.3% Stake in MediWound

T. Rowe Price Associates, Inc. has reported a 4.3% beneficial ownership stake in MediWound Ltd. as of December 31, 2025.

Summary

• T. Rowe Price Associates, Inc. holds beneficial ownership of 554,498 shares of MediWound Ltd. common stock.
• This ownership represents 4.3% of MediWound Ltd.'s outstanding common stock.
• T. Rowe Price Associates, Inc. has sole voting power over 535,181 shares.
• T. Rowe Price Associates, Inc. has sole dispositive power over 554,498 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of MediWound Ltd.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional holding by T. Rowe Price suggests a degree of confidence in MediWound Ltd., although it is a routine disclosure and not an active investment decision announcement.

Positives

• The disclosure of a significant stake by a reputable institutional investor like T. Rowe Price can signal confidence in MediWound Ltd.'s long-term prospects.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• T. Rowe Price Associates, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that the disclosure of a 4.3% stake by T. Rowe Price, a major investment adviser, indicates continued institutional interest in the biotechnology or medical device sector, specifically within companies like MediWound Ltd. This type of filing provides transparency into significant holdings by large asset managers, which can influence market perception and investor sentiment.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding may provide a level of reassurance and potentially attract further institutional interest, positively impacting shareholder confidence.
• Management: Awareness of a large institutional holder may influence management's strategic decisions and communication with the investment community.

Key Dates

Recommendation

This filing is a routine disclosure of beneficial ownership by an institutional investor and does not contain new operational or financial performance data for MediWound Ltd. While the presence of a major investor like T. Rowe Price is generally positive, it does not provide sufficient new information to warrant a change in investment recommendation. A 'hold' recommendation is appropriate as investors should continue to monitor MediWound's fundamental performance and other market factors.

Keywords

MediWound Ltd., T. Rowe Price Associates Inc., Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Institutional Investor